| Literature DB >> 24812434 |
Yoichiro Hirakawa1, Hisatomi Arima1, Sophia Zoungas2, Toshiharu Ninomiya1, Mark Cooper3, Pavel Hamet4, Giuseppe Mancia5, Neil Poulter6, Stephen Harrap7, Mark Woodward1, John Chalmers8.
Abstract
OBJECTIVE: There is no consensus on the importance of visit-to-visit glycemic variability in diabetes. Therefore, we assessed the effects of visit-to-visit variability (VVV) in HbA1c and fasting glucose on major outcomes in the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation) trial. RESEARCH DESIGN AND METHODS: ADVANCE was a factorial randomized controlled trial of intensive glucose control and blood pressure lowering in patients with type 2 diabetes. VVV in the intensive glucose treatment group was defined using the SD of five measurements of HbA1c and glucose taken 3-24 months after randomization. Outcomes were combined macro- and microvascular events and all-cause mortality occurring post 24 months. Sensitivity analyses were performed using other indices of variability and in the standard glucose treatment group.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24812434 DOI: 10.2337/dc14-0199
Source DB: PubMed Journal: Diabetes Care ISSN: 0149-5992 Impact factor: 19.112